AstraZeneca CEO snared more than $18M last year as his company worked through highs and lows of vaccine launch

While AstraZeneca’s 2021 COVID-19 shot sales paled in comparison to Pfizer and Moderna’s vaccine revenues, the British drugmaker remained a pandemic force—and its CEO is poised to collect a hefty pay package for the year.